uploads///fish oil _

What Are Analysts Recommending for AMRN and IOVA in May?

By

May. 22 2019, Updated 8:07 a.m. ET

Stock price movements

On May 17, Amarin (AMRN) closed at $17.79, 2.30% higher than the previous close, 657.02% higher than the 52-week low of $2.35, and 23.76% lower than the 52-week high of $23.33. The company’s market capitalization was $5.75 billion, and its forward PE, PS (price-to-sales), PB (price-to-book), and PC (price-to-cash) ratios were 83.92x, 22.24x, 49.42x, and 27.24x, respectively. Amarin’s 14-day RSI (relative strength index) is currently 48.82. The number of outstanding shares for the company is 323.25 million, while the short float ratio is 15.86%.

Article continues below advertisement

On May 17, Iovance Biotherapeutics (IOVA) closed at $15.03, 1.64% lower than the previous close, 107.02% higher than the 52-week low of $7.26, and 17.64% lower than the 52-week high of $18.25. The company’s market capitalization is $1.89 billion and PB and PC ratios were 4.27x and 4.29x, respectively. Iovance Biotherapeutics’s 14-day RSI is currently 73.63. The number of outstanding shares for the company is 125.57 million, while the short float ratio is 8.03%.

Analysts’ recommendations and target price

The consensus recommendation for Amarin is a “strong buy,” while the consensus recommendation for Iovance Biotherapeutics is a “buy.” Wall Street analysts expect an upside potential of 86.62% for Amarin based on the company’s closing price on May 17. Analysts first reduced the company’s 12-month consensus target price from $34.00 in February and March to $32.60 in April but then raised it to $33.20 in May.

Out of five analysts covering Amarin, three recommend a “strong buy,” and two recommend a “buy.”

Wall Street analysts expect an upside potential of 67.20% for Iovance Biotherapeutics based on the company’s closing price on May 17. Analysts have gradually reduced the company’s 12-month consensus target price from $30.13 in February to $25.29 in March and April to $25.13 in May.

Out of nine analysts covering Iovance Biotherapeutics, four recommend a “strong buy,” and five recommend a “buy.”

Advertisement

More From Market Realist

  • SemiLEDS logo over LED lighting
    Company & Industry Overviews
    There's Still Time to Get in on SemiLEDS (LEDS) Stock
  • Trader on the NYSE
    Company & Industry Overviews
    What Are the Most Expensive Stocks Ever?
  • Michelob Ultra beer
    Company & Industry Overviews
    AB InBev Is the Top Beer Brand Worldwide—Is It a Monopoly?
  • Businesswoman looking out a window
    Company & Industry Overviews
    Shifting Focus: Three Women Investing Funds in 2021
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.